<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038558</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-087</org_study_id>
    <nct_id>NCT00038558</nct_id>
  </id_info>
  <brief_title>Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy</brief_title>
  <official_title>Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy</measure>
    <time_frame>Following ABVD chemotherapy course</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim SD/01</intervention_name>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <other_name>Doxorubicin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <other_name>Bleomycin sulfate</other_name>
    <other_name>Blenoxane</other_name>
    <other_name>BLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <other_name>Velban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTIC</intervention_name>
    <arm_group_label>Filgrastim + ABVD Chemotherapy</arm_group_label>
    <other_name>DTIC-Dome</other_name>
    <other_name>Dacarbazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Previously untreated Hodgkin's disease patients who are scheduled to receive standard
             ABVD chemo.

          -  Histologically proven diagnosis of Hodgkin's disease of any type.

          -  Bidimensionally measurable disease.

          -  Signed informed consent.

          -  Age &gt;/= 16 yrs.

          -  Adequate bone marrow reserve (ANC&gt;1000/uL, Platelet &gt;100,000/uL.

          -  LVEF&gt;/=50% by MUGA scan or echocardiogram.

          -  Serum creatinine &lt;2mg/dL; serum bilirubin&lt;2mg/dL.

        EXCLUSION:

          -  HIV positive.

          -  Pregnant women and those of child bearing age who are not using adequate
             contraception.

          -  Prior chemotherapy.

          -  Severe pulmonary disease including COPD and asthma.

          -  History of prior sensitivity to E.coli derived products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2002</study_first_submitted>
  <study_first_submitted_qc>May 31, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2002</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Dacarbazine</keyword>
  <keyword>DTIC</keyword>
  <keyword>DTIC-Dome</keyword>
  <keyword>Vinblastine</keyword>
  <keyword>Velban</keyword>
  <keyword>Bleomycin sulfate</keyword>
  <keyword>Blenoxane</keyword>
  <keyword>BLM</keyword>
  <keyword>Doxorubicin Hydrochloride</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Pegfilgrastim</keyword>
  <keyword>granulocyte colony-stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

